Vaxcyte
Clinical-stage vaccine company focused on engineering and manufacturing broadly protective conjugate vaccines against bacterial pathogens. The organization develops multivalent pneumococcal conjugate vaccines and early-stage candidates for Group A Streptococcus and Shigella using advanced chemistry and a cell-free protein synthesis approach, and is expanding U.S. manufacturing capacity.
Industries
Nr. of Employees
large (251-1000)
Patents
Optimized cell-free synthesis of invasion plasmid antigen B and related compositions and methods of use
US-12280097-B2
View Details
Optimized cell-free synthesis of invasion plasmid antigen B and related compositions and methods of use
US-12280097-B2
View DetailsProducts
VAX-31 (31-valent pneumococcal conjugate vaccine candidate)
A 31-valent pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal disease with broad serotype coverage; advancing through adult Phase 3 and infant Phase 2 clinical programs.
VAX-24 (24-valent pneumococcal conjugate vaccine candidate)
A 24-valent pneumococcal conjugate vaccine candidate in clinical development intended to increase serotype coverage for prevention of invasive pneumococcal disease.
VAX-A1 (Group A Streptococcus vaccine candidate)
A conjugate vaccine candidate targeting Group A Streptococcus evaluated in preclinical and Phase 1 adult studies to assess safety, tolerability and immunogenicity.
VAX-GI (Shigella vaccine candidate)
A Shigella vaccine candidate in preclinical development targeting prevention of dysentery and shigellosis, supported in part by NIH research grants.
VAX-XL (third-generation pneumococcal candidate, preclinical)
A third-generation pneumococcal conjugate vaccine candidate in preclinical development intended to extend serotype coverage and functionality.
VAX-31 (31-valent pneumococcal conjugate vaccine candidate)
A 31-valent pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal disease with broad serotype coverage; advancing through adult Phase 3 and infant Phase 2 clinical programs.
VAX-24 (24-valent pneumococcal conjugate vaccine candidate)
A 24-valent pneumococcal conjugate vaccine candidate in clinical development intended to increase serotype coverage for prevention of invasive pneumococcal disease.
VAX-A1 (Group A Streptococcus vaccine candidate)
A conjugate vaccine candidate targeting Group A Streptococcus evaluated in preclinical and Phase 1 adult studies to assess safety, tolerability and immunogenicity.
VAX-GI (Shigella vaccine candidate)
A Shigella vaccine candidate in preclinical development targeting prevention of dysentery and shigellosis, supported in part by NIH research grants.
VAX-XL (third-generation pneumococcal candidate, preclinical)
A third-generation pneumococcal conjugate vaccine candidate in preclinical development intended to extend serotype coverage and functionality.
Services
Strategic collaborations and licensing arrangements to scale platform technologies and advance vaccine development programs.
Strategic collaborations and licensing arrangements to scale platform technologies and advance vaccine development programs.
Expertise Areas
- Conjugate vaccine development
- Cell-free protein expression
- Bioconjugation chemistry
- Clinical trial management for vaccines
Key Technologies
- Cell-free protein synthesis
- Site-specific conjugation (click chemistry)
- Non-native amino acid incorporation
- Polysaccharide–protein conjugation
News & Updates
Phase 1/2 randomized clinical trial reporting safety, tolerability and immunogenicity results for the 31-valent pneumococcal conjugate vaccine candidate.
Phase 2 randomized, blinded, dose-finding clinical trial assessing a 24-valent pneumococcal conjugate vaccine candidate in older adults.
Preclinical study describing a Shigella vaccine antigen produced in a cell-free expression system and its broad-spectrum potential.
Multiple peer-reviewed publications (ACS Omega, Nature Communications, NPJ Vaccines, Scientific Reports, etc.) detailing conjugation chemistry, cell-free production and preclinical evaluations.
Phase 1/2 randomized clinical trial reporting safety, tolerability and immunogenicity results for the 31-valent pneumococcal conjugate vaccine candidate.
Phase 2 randomized, blinded, dose-finding clinical trial assessing a 24-valent pneumococcal conjugate vaccine candidate in older adults.
Preclinical study describing a Shigella vaccine antigen produced in a cell-free expression system and its broad-spectrum potential.
Multiple peer-reviewed publications (ACS Omega, Nature Communications, NPJ Vaccines, Scientific Reports, etc.) detailing conjugation chemistry, cell-free production and preclinical evaluations.